Barclays PLC Nuvation Bio Inc. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Barclays PLC holds 1,552,138 shares of NUVB stock, worth $3.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,552,138

Previous 1,605,706 3.34%

Holding current value

$3.63 Million

Previous $5.84 Million 22.45%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $138,205 - $197,665	-53,568 Reduced 3.34%	1,552,138 $4.53 Million
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $1.63 Million - $4.44 Million	1,118,954 Added 229.88%	1,605,706 $5.84 Million
Q4 2023 Feb 15, 2024	BUY	$0.96 - $1.53 $369,065 - $588,197	384,443 Added 375.77%	486,752 $735,000
Q3 2023 Nov 07, 2023	SELL	$1.26 - $2.1 $3,584 - $5,974	-2,845 Reduced 2.71%	102,309 $137,000
Q2 2023 Aug 03, 2023	SELL	$1.56 - $1.84 $186,145 - $219,556	-119,324 Reduced 53.16%	105,154 $190,000
Q1 2023 May 04, 2023	BUY	$1.6 - $2.48 $249,625 - $386,919	156,016 Added 227.89%	224,478 $371,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $20,007 - $29,772	11,909 Added 21.06%	68,462 $132,000
Q3 2022 Nov 03, 2022	BUY	$0.29 - $4.04 $979 - $13,643	3,377 Added 6.35%	56,553 $127,000
Q2 2022 Aug 12, 2022	SELL	$3.24 - $5.85 $25,097 - $45,314	-7,746 Reduced 12.71%	53,176 $172,000
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $280,241 - $537,941	60,922 New	60,922 $321,000

Others Institutions Holding NUVB

# of Institutions

152

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $508M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account